List of Excipients in Branded Drug PROCHIEVE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Columbia Laboratories	PROCHIEVE	progesterone	55056-0406	CARBOMER 934
Columbia Laboratories	PROCHIEVE	progesterone	55056-0406	GLYCERIN
Columbia Laboratories	PROCHIEVE	progesterone	55056-0406	HYDROGENATED PALM OIL
Columbia Laboratories	PROCHIEVE	progesterone	55056-0406	MINERAL OIL
Columbia Laboratories	PROCHIEVE	progesterone	55056-0406	POLYCARBOPHIL
Columbia Laboratories	PROCHIEVE	progesterone	55056-0406	SODIUM HYDROXIDE
Columbia Laboratories	PROCHIEVE	progesterone	55056-0406	SORBIC ACID

Prochieve Excipient Strategy and Commercial Opportunities for Progesterone Vaginal Gel

Last updated: September 24, 2026

Prochieve is a progesterone vaginal gel product built around a bioadhesive, water-based delivery system. Its commercial value is concentrated in formulation performance rather than in a complex active pharmaceutical ingredient. The principal excipient strategy is to retain vaginal residence time, support progesterone release, control gel rheology, and limit irritation while preserving a simple regulatory pathway.

The strongest opportunities are generic or 505(b)(2) development of progesterone vaginal gel, improved applicator systems, lower-irritation formulations, and differentiated products for fertility treatment, luteal-phase support, and secondary amenorrhea. Excipient changes that materially alter absorption, local tolerability, microbiome effects, or dosing frequency could create regulatory and intellectual-property value.

What is Prochieve and how does its formulation work?

Prochieve is a progesterone vaginal gel containing either 4% or 8% progesterone, depending on the dosage strength. The 8% product delivers 90 mg of progesterone in approximately 1.125 g of gel. The product was developed for vaginal administration, where the formulation is intended to adhere to mucosal tissue and provide sustained local delivery of progesterone [1].

Attribute	Prochieve profile
Active ingredient	Progesterone
Dosage form	Vaginal gel
Principal strengths	4% and 8%
Example 8% dose	90 mg progesterone
Route	Vaginal
Delivery objective	Local adhesion with sustained progesterone release
Regulatory category	Prescription drug
Original sponsor	Columbia Laboratories, Inc.
FDA application	NDA 020701
Primary therapeutic areas	Secondary amenorrhea and assisted-reproduction-related progesterone support

The formulation uses a carbomer or carbomer-type polymer system, glycerin, light mineral oil, polycarbophil, and purified water. The exact inactive-ingredient composition and manufacturing controls should be taken from the applicable FDA labeling and regulatory record before development decisions are made [1, 2].

What excipients are used in Prochieve?

The key excipients are functional rather than merely dilutive. Each contributes to the product’s performance profile.

Excipient class	Likely function in Prochieve
Carbomer polymer	Viscosity, gel structure, and controlled drug release
Polycarbophil	Mucoadhesion and prolonged vaginal residence
Glycerin	Humectant and solvent; affects osmolality and feel
Light mineral oil	Emollient and rheology modifier
Purified water	Continuous phase and solvent
pH-adjusting components	Gel formation and vaginal compatibility, where applicable

Carbomer and polycarbophil

Carbomer and polycarbophil are central to the product’s excipient strategy. Carbomer provides a cross-linked polymer network that converts an aqueous vehicle into a viscous gel. Polycarbophil contributes adhesion to mucosal surfaces and can extend the residence time of the dose after administration.

The formulation balance is sensitive. More polymer can improve retention but may increase residue, applicator resistance, and patient discomfort. Less polymer can improve spreadability but may reduce vaginal residence time and increase leakage. The development target is not maximum viscosity. It is adequate retention at an acceptable patient-use profile.

Glycerin

Glycerin supports hydration and contributes to the product’s texture. Its concentration affects osmolality, water activity, viscosity, and local tolerability. A high-osmolality vaginal formulation may increase discomfort or epithelial irritation in some patients. A reformulator should treat glycerin concentration as a performance variable, not as an inert quantity.

Light mineral oil

Light mineral oil can improve lubrication and modify the feel and rheology of the gel. It may also affect drug partitioning and release from the polymer matrix. Its use should be assessed against compatibility with the applicator, packaging extractables, cleaning performance, and patient acceptability.

What formulation attributes are commercially protectable?

The highest-value formulation attributes are those that can be measured in comparative clinical or laboratory studies. A broad claim to “progesterone vaginal gel” is likely to face prior-art pressure. More defensible opportunities may involve a specific combination of excipients, defined polymer grades, rheological limits, release profiles, or product-use characteristics.

Potentially protectable features include:

1. A defined carbomer-polycarbophil ratio.
2. A narrow viscosity or yield-stress range.
3. A progesterone particle-size distribution or dispersion state.
4. A specified pH and osmolality range.
5. A preservative-free composition with extended stability.
6. A formulation that reduces leakage or dosing residue.
7. A formulation with improved vaginal residence time.
8. A package and applicator combination that delivers a controlled dose.
9. A lower-irritation composition compatible with fertility-treatment use.
10. A composition that maintains performance across defined storage conditions.

A patent strategy based only on excipient identity is weaker than one tied to composition ranges and measurable performance. For example, claims covering “progesterone, carbomer, polycarbophil, glycerin, mineral oil, and water” may be vulnerable if comparable vaginal progesterone gels are disclosed. Claims tied to a specific rheology profile, release curve, stability result, or clinical tolerability advantage have greater potential value.

What commercial opportunities exist for Prochieve excipient development?

Generic progesterone vaginal gel

The most direct opportunity is a generic version of the reference product. A developer could seek approval through an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements. The formulation would need to match the reference product closely enough to avoid unnecessary clinical and regulatory risk.

Key development risks include:

• Difficulty reproducing polymer grade and gel rheology.
• Differences in vaginal residence time.
• Variable progesterone release.
• Applicator dose-delivery variation.
• Product residue and leakage.
• Local irritation or altered vaginal tolerability.
• Packaging compatibility and stability.

A generic developer may prefer a formulation that is compositionally close to Prochieve but uses current, well-documented excipient suppliers and improved process controls.

505(b)(2) reformulation

A 505(b)(2) pathway could support a differentiated product that relies partly on existing progesterone safety and efficacy information but changes the formulation, dosage strength, delivery system, or dosing schedule. Possible development concepts include:

• A lower-residue gel.
• A once-daily formulation with longer mucosal residence.
• A lower-volume formulation delivering the same progesterone dose.
• A formulation with improved applicator ergonomics.
• A preservative-free product with improved storage stability.
• A vaginal gel designed for reduced leakage during daily activity.
• A product optimized for patients who discontinue treatment because of local discomfort.

A 505(b)(2) strategy would require a clear clinical or pharmacokinetic rationale. Excipient changes that alter systemic exposure or tissue distribution could trigger additional clinical requirements.

Fertility-clinic and assisted-reproduction products

Progesterone vaginal products are used in fertility-treatment settings where adherence, convenience, and tolerability can influence treatment continuity. A differentiated excipient system could compete on:

• Reduced dosing frequency.
• Less leakage.
• Less applicator mess.
• Better comfort during prolonged use.
• Improved packaging for multi-week treatment cycles.
• Compatibility with clinic dispensing and patient education.

A product positioned for assisted reproduction would compete with vaginal inserts, capsules, and other progesterone gels. Excipient innovation must therefore produce a visible patient or provider benefit rather than a technical change with no use advantage.

How does Prochieve compare with other progesterone dosage forms?

Product category	Formulation advantage	Main commercial limitation
Vaginal gel	Mucoadhesion and local delivery; noninvasive	Leakage, residue, variable patient acceptance
Vaginal insert	Defined unit dose and reduced handling	May cause discharge or insertion discomfort
Vaginal capsule	Familiar dosage form and flexible manufacturing	Leakage and dissolution variability
Oral progesterone	Simple administration	Systemic adverse effects and first-pass metabolism
Injectable progesterone	Predictable systemic exposure	Pain, administration burden, and clinic dependence
Transdermal systems	Noninvasive systemic delivery	Skin permeability and patch adhesion constraints

Prochieve’s excipient platform is most competitive against vaginal progesterone products, not against all progesterone therapies. The commercial proposition depends on combining adequate vaginal residence with minimal residue and consistent dose delivery.

What FDA regulatory issues affect a Prochieve follow-on?

FDA review would focus on pharmaceutical equivalence, product quality, bioequivalence, and the effect of formulation differences on progesterone exposure. A developer should expect scrutiny of the following:

Quality and manufacturing

Critical quality attributes include:

• Progesterone assay and content uniformity.
• Particle size and dispersion.
• Gel viscosity and rheology.
• pH and osmolality.
• Microbial limits.
• Preservative or preservative-free controls.
• Stability after package opening or dose removal.
• Extractables and leachables.
• Applicator fill weight and delivered dose.

The manufacturing process must control polymer hydration, mixing order, shear exposure, deaeration, and filling. Small process changes can affect viscosity and drug release even when the qualitative excipient list is unchanged.

Bioequivalence and local delivery

For a vaginal gel, systemic pharmacokinetics may not fully capture local performance. FDA may consider the relationship between formulation composition, progesterone exposure, dosage delivery, and clinical effect. A reformulated product that changes mucoadhesion or release could require more evidence than a close qualitative and quantitative copy.

FDA exclusivity and Orange Book status

Prochieve is an older product, and its commercial and regulatory status should be verified against the current FDA Drugs@FDA database, Orange Book, and discontinued-drug records before filing or licensing. Historical approval does not establish current market availability, active exclusivity, or current patent protection.

For an older progesterone vaginal gel, the primary regulatory opportunity is generally unlikely to depend on unexpired new-drug exclusivity. The relevant barriers are more likely to be product-specific bioequivalence, formulation know-how, manufacturing reproducibility, and any surviving patent or regulatory claims.

What patents protect Prochieve and its excipient system?

The original product may have been covered by formulation, delivery, and use patents associated with Columbia Laboratories and related entities. Patent protection for an older vaginal progesterone product must be analyzed by claim, expiration date, terminal disclaimer, maintenance status, and jurisdiction.

The practical patent questions are:

• Whether any patent remains unexpired.
• Whether the patent is listed for the specific NDA.
• Whether claims cover the composition, dosage form, method of use, or manufacturing process.
• Whether a generic applicant would face a Paragraph IV certification.
• Whether the claims cover the current marketed product or only historical formulations.
• Whether continuation or divisional patents remain relevant.
• Whether the patents have expired in the United States, Europe, Canada, or other target markets.

A search limited to the brand name is inadequate. The analysis should include progesterone vaginal gel, bioadhesive vaginal compositions, polycarbophil delivery systems, carbomer formulations, and Columbia Laboratories patent families.

Are Paragraph IV challenges and litigation risks material?

A generic applicant could face Paragraph IV issues if an Orange Book-listed patent remains active. The commercial risk would depend on the patent’s remaining term, claim breadth, holder’s litigation posture, and whether a 30-month stay is available.

For an older product, the greater risk may be technical rather than litigation-driven. A developer that cannot reproduce the reference product’s release and residence characteristics may face an extended development program even if no enforceable patent blocks entry.

Relevant litigation diligence should cover:

• FDA Orange Book patent listings.
• Federal district court filings under the Hatch-Waxman statute.
• ANDA notices involving progesterone vaginal gel.
• Patent assignment records.
• Settlement agreements and launch licenses.
• Prior proceedings involving Columbia Laboratories, progesterone gels, or polycarbophil delivery systems.

No current Paragraph IV challenge, settlement agreement, or active Prochieve litigation should be inferred without a current docket and FDA-record review.

What manufacturing and excipient barriers could limit competition?

The principal manufacturing barrier is process reproducibility. Carbomer and polycarbophil systems are sensitive to raw-material grade, hydration conditions, mixing energy, neutralization, and entrapped air. A formulation can meet assay specifications yet fail to match the reference product’s use characteristics.

Commercially important controls include:

• Qualified polymer suppliers.
• Tight incoming-material specifications.
• Defined hydration and mixing sequence.
• In-process rheology testing.
• Automated fill-weight control.
• Low-shear filling where required.
• Container-closure compatibility.
• Stability testing in final packaging.
• Applicator performance across temperature conditions.

The most defensible know-how may sit in the process rather than in the ingredient list. This favors manufacturers with experience in semisolid vaginal products and polymer-based drug delivery.

What is the commercial outlook for Prochieve-type products?

A Prochieve-type product has three viable commercial positions:

1. A low-cost generic that closely matches the reference gel.
2. A 505(b)(2) product with improved tolerability, retention, or convenience.
3. A fertility-focused product with differentiated packaging and patient-use features.

The generic opportunity depends on market size, current competitor count, and the availability of an approved reference product. The differentiated opportunity depends on evidence that the excipient system improves adherence or clinical usability.

Revenue exposure is likely to be driven by treatment volume and reimbursement rather than by excipient cost. Excipients themselves are inexpensive relative to clinical development, quality testing, packaging, and commercialization. The economic value comes from reducing dose frequency, limiting treatment discontinuation, improving manufacturing yield, or supporting premium positioning.

Key Takeaways

• Prochieve is a progesterone vaginal gel using a polymer-based, mucoadhesive delivery system.
• Carbomer, polycarbophil, glycerin, light mineral oil, and purified water are central to the formulation strategy.
• The strongest formulation opportunities involve rheology, residence time, leakage reduction, irritation control, and applicator performance.
• A close generic copy may be more practical than a broad reformulation if the reference product remains available for comparison.
• A 505(b)(2) strategy is more attractive when the reformulation delivers a measurable patient or clinical-use benefit.
• Patent value depends on surviving claims covering formulation, delivery, use, or manufacturing rather than on the Prochieve brand name alone.
• Current Orange Book listings, exclusivity, Paragraph IV activity, litigation, and settlement status require live FDA and court-record verification.
• Manufacturing know-how may be a stronger barrier than the ingredient list because polymer hydration and gel rheology are process-sensitive.

FAQs

Is Prochieve a bioadhesive vaginal gel?

Yes. Its polymer system is intended to increase vaginal residence time and support sustained progesterone delivery.

Which excipient is most important in a Prochieve follow-on?

The carbomer-polycarbophil system is the most important because it controls gel structure, adhesion, residence time, and release behavior.

Can a company make a generic Prochieve with different excipients?

Potentially, but the changed formulation would need to satisfy applicable FDA requirements for equivalence, quality, performance, and safety. A materially different formulation may require a 505(b)(2) pathway rather than an ANDA.

What is the main patient-use weakness of progesterone vaginal gel?

Leakage, residue, applicator inconvenience, and local discomfort can reduce acceptance during repeated or prolonged treatment.

Are excipient patents likely to block a Prochieve competitor?

For an older product, the risk depends on the status and scope of surviving patents. Current FDA listings, patent records, and litigation dockets must be reviewed before concluding that a blocking patent exists.

References

1. U.S. Food and Drug Administration. (2007). Prochieve progesterone vaginal gel prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2017). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA.

5. U.S. Food and Drug Administration. (2020). Product-specific guidance for generic drug development. FDA.